REG - Scancell Hlds - Scancell to present at ASCO Annual Meeting

Scancell HoldingsAnnouncement

24/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240524:nRSX7479Pa&default-theme=true

RNS Number : 7479P  Scancell Holdings Plc  24 May 2024

24 May 2024

 

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell to present at the 2024 ASCO Annual Meeting

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, is pleased to announce that it
will be presenting during a poster session at the American Society of Clinical
Oncology (ASCO) Annual Meeting, taking place from 31 May to 4 June 2024, in
Chicago, Illinois.

 

Scancell will be presenting a poster highlighting data from its open-label
Phase 2 SCOPE trial, investigating its cancer vaccine, SCIB1, in combination
with checkpoint inhibitors (CPIs) in advanced melanoma. Exceptional results
from the first 13 patients receiving SCIB1 have already been demonstrated,
with an objective response rate of 85%.

 

Professor Lindy Durrant, Chief Executive Officer of Scancell, said: "ASCO is
one the leading events for companies working in the field of oncology and so
we were very proud to be selected to present a poster at this year's
conference.  Our ongoing Phase 2 SCOPE trial of our melanoma cancer vaccine,
SCIB1, has shown highly promising efficacy and safety data so far and we are
hugely excited to highlight the progress Scancell is making in the cancer
vaccine space."

 

Poster presentation details

 

Title: A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab +
ipilimumab in patients with advanced unresectable melanoma: Efficacy and
safety results from the open-label phase 2 SCOPE trial.

Session type and title: Poster Session - Melanoma/Skin Cancers

Session date and time: 1 June 2024, 1:30 PM - 4:30 PM CDT

 

 

If you would like to arrange a meeting at the conference, please contact
commercial.enquiries@scancell.co.uk
(mailto:commercial.enquiries@scancell.co.uk) .

 

 

-ENDS-

 

 For further information, please contact:
 Scancell Holdings plc                                                +44 (0) 20 3709 5700
 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)  +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)
 Nick Harland / Ben Good (Corporate Broking)

 WG Partners LLP (Joint Broker)                                       +44 (0) 20 3705 9330
 David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

 Panmure Gordon (UK) Limited (Joint Broker)                           +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 

 ICR Consilium                                  +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville  scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKXLFLZELXBBZ